Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

PsyBio Therapeutics Corp V.PSYB


Primary Symbol: V.PSYB.H Alternate Symbol(s):  PSYBF

PsyBio Therapeutics Corp. is a Canada-based biotechnology company. The Company is focused on discovering, designing and developing psycho-focused therapeutics to improve mental and neurological conditions. It is focused on understanding the value of tryptamines and other related psycho-targeted molecules as therapeutic candidates to improve mental and neurological health. The Company is engaged in research and development for occurring psychoactive tryptamines, which is originally discovered in different varieties of hallucinogenic mushrooms, other tryptamines and phenethylamines, and combinations thereof. The Company utilizes a bio-medicinal chemistry approach to therapeutic development, in which psychoactive compounds can be utilized as a template upon, which to develop precursors and analogs, both naturally and non-naturally occurring.


TSXV:PSYB.H - Post by User

Post by partystockeron Dec 19, 2021 5:36pm
248 Views
Post# 34245308

$ORIG- to IPO soon

$ORIG- to IPO soon

The therapeutic psychedelic industry is expected to grow at a CAGR of 16.3% to reach a market value of $10.75 billion by 2027. The rapidly increasing acceptance of psychedelic treatments is creating a strong demand from therapists and patients for access to the new products and therapies.


One of the Canadian players I’m keeping an eye on right now is psychedelic fund Origin Therapeutics. Origin Therapeutics is expected to IPO before the end of the quarter under the ticker $ORIG. $ORIG will provide investors with exposure to both public and private companies, giving investors exposure to rapidly growing companies that would otherwise be unavailable. 


Origin announced their official leadership team earlier this month, and it looks like they’ve assembled a strong group. 


I’m looking forward to hearing more concrete dates on $ORIG’s IPO as I’m expecting them to be a serious stock to watch once the psychedelic industry begins to swing back. 


https://www.bcbusiness.ca/BCs-functional-and-psychedelic-mushroom-industry-is-having-a-shroom-boom

 
<< Previous
Bullboard Posts
Next >>